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Kingdom
Hypothalamo-pituitary-adrenal (HPA) axis activity is subject to negative feedback control by glu-
cocorticoids. Although the rapid component of this feedback is widely considered to contribute to
regulation of dynamic HPA activity, few in vivo data exist on the temporal and pharmacological
characteristics of this phenomenon. Thus, frequent automated blood samplingwas undertaken in
rats to determine the effects of acute glucocorticoid administration on basal and stress-induced
corticosterone secretion. The glucocorticoid agonist methylprednisolone (5–2000 g) or dexa-
methasone (5–500 g) injected iv at the peak of the diurnal rhythm caused dose-dependent sup-
pression of basal corticosterone secretion, which was attenuated by the glucocorticoid receptor
antagonist RU38486.With 50 gmethylprednisolone, the onset of this suppression occurred at 40
min and remained significant for 120 min. However, although higher doses led to a greater and
more sustained suppression of endogenous corticosterone, the responsewas delayed by the emer-
gence of an initial stimulatory response that imposed a finite minimum delay. A corticosterone
response to injection of CRH (1 g, iv) during the period of maximal suppression indicated a
suprapituitary site for the inhibitory effect glucocorticoid activation. This mechanism was sup-
ported by glucocorticoid injection immediately before a psychological stress (30min, white noise);
methylprednisolone caused dose-dependent attenuation of stress-induced corticosterone release
and expression of the activity marker c-fosmRNA in the paraventricular nucleus but did not block
the pituitary response to CRH. Thus, in rats, glucocorticoid receptor activation rapidly suppresses
basal and stress-induced HPA activity that operates, at least in part, through a central mechanism
of action. (Endocrinology 153: 200–211, 2012)
The hypothalamo-pituitary-adrenal (HPA) axis is sub-ject to negative feedback control by endogenous ad-
renal corticosteroids, which has been shown to act in sev-
eral distinct time domains. In addition to delayed steroid
feedback that regulates long-term changes in the synthesis
of both CRH in the paraventricular nucleus (PVN) and
ACTH in pituitary corticotrophs (1–6), more rapid effects
have been suggested to contribute to the dynamic regula-
tion of the axis (7–10). These rapid actions of corticoste-
roids are thought to operate either at the pituitary (11, 12)
or suprapituitary levels (13, 14) and have been postulated
to play important roles both in terminating the response to
acute stressors (15–17) and in generating the ultradian
pattern of basal HPA activity (18, 19).
Although rapid corticosteroid feedback was first pro-
posed nearly 40 yr ago and has become widely accepted as
a mechanism regulating HPA activity, data supporting the
temporal dynamics and pharmacological characteristics
of this phenomenon are relatively scant. The majority of
studies supporting fast feedback have involved adminis-
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tration of corticosteroids shortly before either application
of different stressors (11, 14, 20–25) or injection of CRH
(11, 12, 14) to demonstrate attenuation of the secretion of
ACTH. However, relatively few studies have examined
the acute effects of corticosteroid feedback on basal (un-
stimulated) HPA activity. Early studies in rats (26) and
dogs (27, 28) showed that bolus injection or infusion of
cortisol caused a suppression of ACTH levels with a fixed
lag of 20 min that was not reduced at higher doses. How-
ever, in these cases, the animals were both anesthetized
and adrenalectomized, and no control infusions were per-
formed. Later, Keller-Wood (21) showed that infusion of
cortisol caused a significant suppression of basal ACTH
levels in intact, conscious dogs, also with a delay of 40 min,
although animals were restrained throughout this proce-
dure. Studies in humans have shown that injections or
infusions of corticosteroids can have a suppressive effect
on basal ACTH release with onset delay of less than 1 h
(10, 29–34), providing strong evidence for a rapid com-
ponent of inhibition. In rodents, high doses of the corti-
costeroid agonist prednisolone sodium succinate (5 or 50
mg/kg iv) cause rapid decline of plasma corticosterone,
reaching undetectable levels within 1 h and remaining un-
detectable for 4–6 h (35). More recently, using repeated
blood sampling in rats, we have shown that acute iv in-
jection of 2 mg methylprednisolone can both block the
HPA response to 10 min noise stress 40 min later and
suppressbasal corticosterone levelswhen testedduring the
morning nadir (23) and that lower doses [500 g (8) and
250g (9)] rapidly suppress basal corticosterone secretion
at the diurnal acrophase.
To further characterize the pharmacology and tempo-
ral profile of rapid glucocorticoid suppression of HPA
activity, we have studied the effects of acute, exogenous
doses of the synthetic glucocorticoids methylprednisolone
and dexamethasone on basal HPA activity measured using
automated blood sampling of unhandled animals. Fur-
thermore, to determine whether the effects occurred at a
pituitary and/or central site of action, the ability of meth-
ylprednisolone to attenuate either CRH- or stress-induced
HPA activity was examined.
Materials and Methods
Animal husbandry and cannulation
All experiments were performed on virgin female Sprague
Dawley rats (250–350 g) obtained from Bantin and Kingman
(Hull, UK) and housed in the local animal facility at least 7 d
before experimentation, initially in groups of four to six per cage.
Female rats were used because the higher basal levels of corti-
costerone compared with males (36) enabled better resolution of
the temporal profile of glucocorticoid inhibition. Animals were
housed under standard environmental conditions: 14-h light,
10-h dark cycle (lights on at 0500 h) and ad libitum access to
water and rat chow. The iv cannulation of the right jugular vein
was performed as previously described (37). Surgery was per-
formed at least 3 d before blood sampling to allow for postop-
erative recovery and adaptation to the sampling environment.
Animals were housed singly after surgery, and a swivel allowed
complete freedom of movement within the home cage. Cannulae
were flushed with a small volume of heparinized saline (10 U/ml)
daily to maintain patency. Procedures were carried out in accor-
dance with the United Kingdom Animals (Scientific Procedures)
Act of 1986 and the European Community Council Directive
(86/609/EEC). Each animal underwent only one period of
sampling.
Blood sampling and drug administration
Blood sampling was undertaken in a sound-isolated room
using an automated sampling system (38). Animals were con-
nected to the system through a liquid swivel and samples (37 l
whole blood diluted 1:5 in heparinized saline) automatically
withdrawn every 5 or 10 min and replaced by heparinized saline.
This procedure for multiple blood sampling does not cause any
adverse effects (8, 9, 23, 25, 36, 37). The initial 1 h of samples was
discarded to avoid any nonspecific release and measurements
commenced either at 1600 h (late light phase) or 0700 h (early
light phase). Injections of steroids, CRH, or vehicle were per-
formed manually by briefly disconnecting the iv cannula from
the swivel and injecting through the sampling cannula. This pro-
cedure was completed between two samples and caused minimal
disturbance. Drug effects were controlled by comparison with
injections of saline.
Study 1: measures of clearance rate of
corticosterone and steroid cross-reaction
Because studies involved the determination of plasma corti-
costerone levels during injection of glucocorticoid agonists, a
study was performed to examine whether measurements were
affected by cross-reaction of the agonists. Seven animals under-
went bilateral adrenalectomy at the same time as cannulation. In
the postoperative period, they were allowed access to drinking
water containing 0.9% NaCl and 0.25 mg/ml corticosterone to
maintain hydromineral balance. On the fourth day at 1200 h,
this solution was replaced by drinking water containing 0.9%
NaCl alone to allow the corticosterone to clear from the circu-
lation. At 1600 h, blood samples were withdrawn every 5 min for
a period of 6 h. At 25, 125, and 225 min of sampling, each animal
received injections of 400 g corticosterone (Sigma-Aldrich, St.
Louis, MO), 2000 g methylprednisolone (sodium succinate,
Solu-Medrone; Pharmacia & Upjohn Ltd., Milton Keynes, UK),
and 500g dexamethasone (dexamethasone-21-phosphate; Sig-
ma-Aldrich), respectively. These doses represented the maximum
doses administered during the later pharmacological studies. Sam-
ples were assayed for corticosterone-like immunoreactivity and
measured values used to calculate cross-reaction. Exponential re-
gression was used to calculate the clearance rate (y y0e
kt) and
half-life [t1⁄2  (ln 2)/k], where y0 is the peak corticosterone value
(nanograms per milliliter), k is the rate constant, and t is time.
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Study 2: effect of glucocorticoid agonists and
antagonist on basal HPA activity
To examine the acute effects of glucocorticoid agonists on
basal HPA activity, animals were administered injections of
methylprednisolone (5g, n 8; 50g, n 10; 500g, n 12;
2000g, n10), dexamethasone (5g, n8; 50g, n6; 500
g, n 7), or saline vehicle (n 11), each in a volume of 0.1 ml.
Injections were made during the late light period to coincide with
the phase of the diurnal cycle when basal corticosterone secretion
is near maximum (23, 37). The dynamics of the response to
agonist injection were examined by rapid blood sampling ev-
ery 5 min for 3 h and then every 10 min for 2 h. In all cases,
samples were collected from 1600 h (3 h before lights off), and
agonist injections were given at 1645 h. To determine the
effect of glucocorticoid antagonism on the response to meth-
ylprednisolone, additional groups of animals were injected
with either 50 g/rat (n  6) or 500 g/rat (n  6) of the
antagonist RU38486 (mifepristone; gift from Dr. J. K. Bela-
noff, Corcept Therapeutics Inc., Menlo Park, CA) 15 min
before injection of 50 g methylprednisolone.
Study 3: CRH challenge during
glucocorticoid-induced suppression
To determine whether glucocorticoid-induced suppression of
HPA activity was due to suppression of pituitary-adrenal re-
sponsiveness, animals were tested for responses to CRH injec-
tion. Samples were collected every 5 min starting at 1500 h,
although measurements did not start until 1600 h. Acute injec-
tion of methylprednisolone (500 g) or saline was given at
1700 h, and CRH (1 g/rat, iv) was injected at either 1800 or
2000 h. CRH (Bachem, Torrance, CA) was diluted in heparin-
ized saline and stored at 4 C until use. The two time points for
CRH injection (60 or 180 min after methylprednisolone) were
selected to coincide with either 1) the period of maximal rate of
change of corticosterone levels or 2) the period of maximal sup-
pression of the axis. Blood sampling continued every 5 min for
a minimum of 2 h after the CRH injection before changing to
every 10 min.
Study 4: rapid glucocorticoid suppression of
stress-induced HPA activity
To determine whether glucocorticoid feedback could rapidly
suppress HPA activity induced by acute psychological stress,
methylprednisolone (500 g) or saline was injected iv 15 min
before the onset of a 30-min noise (104 dB). Sampling was un-
dertaken in the early light phase starting at 0600 h when basal
corticosterone levels were low, and the noise stress commenced
at 0800 h. Blood samples were collected every 5 min until 1200 h.
At 15 min after the end of the noise stress, all animals received an
iv injection of 1 g CRH to determine pituitary-adrenal axis
reactivity during the period of maximal poststress decline in cor-
ticosterone levels.
Finally, to demonstrate both the dose dependency and central
site of action for the glucocorticoid-mediated suppression of
stress-induced HPA activity, groups of animals were injected iv
15 min before the onset of a noise stress (30 min at 104 dB) with
different doses of methylprednisolone (5 g, n  6; 50 g, n 
5; or 500 g, n  5) or saline (n  6). No automated sampling
was conducted, but animals were decapitated immediately after
the end of the noise, and trunk blood (4 ml) was collected. Six
other animals injected with saline were not exposed to noise but
were euthanized at the equivalent time after injection. Trunk
blood samples were centrifuged at 5000 rpm for 5 min, and
plasma was collected and stored at20 C. Brains were removed
and immediately stored at80 C for later determination of c-fos
mRNA expression.
Measurement of corticosterone
Total plasma corticosterone levels were measured by RIA in
diluted whole blood samples (automated sampling) or in plasma
(trunk blood) using a citrate buffer (pH 3.0) to denature the
binding globulin, [125I]corticosterone (0.37 MBq/ml activity;
ICN, High Wycombe, UK), and a specific rabbit antirat corti-
costerone primary antibody (gift courtesy of Professor G. Ma-
kara, Institute of Experimental Medicine, Budapest, Hungary)
(see Ref. 8 for additional details). All samples from an individual
animal were assayed together.
In situ hybridization histochemistry for c-fos mRNA
The hypothalamic PVN was cryosectioned at 12m and sec-
tions mounted on gelatin-coated slides, with the presence of the
PVN confirmed by staining adjacent sections with toluidine blue.
Before hybridization, sections were fixed in 4% paraformalde-
hyde, washed in saline/triethanolamine containing 0.25% acetic
anhydride, dehydrated in ethanol and chloroform, and air dried.
The c-fos mRNA levels were measured by in situ hybridization
using a cDNA riboprobe as described elsewhere (39). Hybridized
sections were apposed to autoradiographic film for 14 d. Rela-
tive levels of c-fos mRNA expression were calculated as OD
measurements using computerized image analysis software (Im-
age; National Institutes of Health, Bethesda, MD).
Data analysis
Hormone data are presented as the mean and SEM of the ab-
solute measures of plasma corticosterone. However, to deter-
mine the time course of the effect of acute agonist injection on
plasma corticosterone levels, a normalization procedure was
also applied. This normalization involved first calculating the
average corticosterone levels in the preinjection period (0–45
min.) for each animal and then dividing all data for that animal
by this average value. Second, to overcome the nonstationary
nature of the data, the rescaled value at each time point was
divided by the respective mean value for that time point in the
saline control group. Thus, the mean normalized value at all time
points for the saline controls was fixed at 1, and treatment groups
are displayed relative to this to show the drug effect. Both raw
and normalized data are presented. To determine the period of
significant steroid-induced effect, t tests were performed on these
normalized values at each time point to determine the first and
last points that differed significantly (P  0.05) from controls.
Other comparisons were performed using t test or ANOVA, as
appropriate.
Results
Study 1: measures of corticosterone clearance and
steroid cross-reaction
Injection of 400 g corticosterone into adrenalecto-
mized rats resulted in a rapid increase of measured corti-
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costerone levels that rose to 1326  297 ng/ml within 5
min (Fig. 1). After peaking, immunoreactive steroid levels
declined back to baseline with an exponential decay: rate
constant 0.143 and calculated half-life 4.8 min. In con-
trast, injection of 2000 g methylprednisolone caused
only a very small increase in plasma steroid immunoreac-
tivity, which peaked at the equivalent of 7.7  1.4 ng/ml
corticosterone and which lasted for 10 min (Fig. 1, inset).
This equates to less than 0.1% of an equivalent dose of
corticosterone. No measurable change in plasma cortico-
sterone immunoreactivity was detected after injection of
500 g dexamethasone.
Study 2: effect of glucocorticoid agonists and
antagonist on basal HPA activity
Before injection of the glucocorticoid agonists, mean
basal corticosterone levels ranged from 80–220 ng/ml,
with a trend toward an increase across the time series re-
flecting the rising levels toward the diurnal acrophase at
lights off (1900 h). These levels are within the range ex-
pected for female Sprague Dawley rats at the late light
phase of the diurnal cycle (37). Injection of saline evoked
no immediate change in corticosterone levels, but there
was a slow decline in levels over the following 4 h in line
with the normal diurnal decline that follows the acrophase
to reach a stable level of 40–80 ng/ml (Fig. 2A). Injection
of increasing doses of methylprednisolone caused a dose-
dependent increase in the magnitude of this suppression,
which at the highest dose persisted through to the end of
the sampling period (Fig. 2E). The temporal profile of this
steroid-induced inhibition was resolved by applying a pro-
portional normalization procedure (Fig. 2, F–J). This re-
vealed that injection of 5g methylprednisolone had little
effect on corticosterone levels (Fig. 2G), but higher doses
caused dose-dependent suppression with a very clear tem-
poral profile. Fifty micrograms of methylprednisolone
caused a suppression of corticosterone levels that was sig-
nificant 40 min after injection and that was no longer
significantly below control levels at 160 min (Fig. 2H).
Notably, although a 10-fold higher dose extended the pe-
riod of suppression such that recovery did not occur until
275 min after injection, the onset was delayed until 80 min
(Fig. 2I). This was apparently due to a small, but not sig-
nificant, stimulatory effect immediately after injection.
This acute stimulatory effect was more pronounced and
significant 15–25 min after injection of 2000 g methyl-
prednisolone (Fig. 2J). At this dose, significant suppres-
sion was detected 65 min after injection and persisted
through to the end of sampling (315 min after injection).
Similar temporal profiles were observed after injection
of dexamethasone but at lower doses than those of meth-
ylprednisolone: injection of 5 g caused significant sup-
pression of plasma corticosterone between 95 and 205
min after injection (Fig. 3F), 50 g suppressed levels be-
tween 50 and 195 min after injection (Fig. 3G), whereas
500 g caused a significant stimulatory effect 15–20 min
after injection followed by a persistent suppression that
commenced 55 min after injection (Fig. 3H).
Administration of the glucocorticoid receptor (GR) an-
tagonist RU38486 15 min before injection of 50g meth-
ylprednisolone modified the temporal profile of the ste-
roid-induced suppression. When the antagonist was
administered at an equivalent dose (50g) the onset of the
suppression was unaffected, but recovery occurred earlier,
with significant differences between groups at 150–155
and 170–180 min after injection (Fig. 4A). A higher an-
tagonist dose (500 g) caused a variable effect, either
blocking the inhibition or, in some animals, evoking a
significant stimulation of corticosterone levels (Fig. 4B).
Study 3: CRH challenge during glucocorticoid-
induced suppression
To test pituitary-adrenal responsiveness during steroid-
induced suppression of corticosterone secretion, CRH in-
jections were performed after acute administration of
methylprednisolone. Injection of CRH (1 g, iv) at the
time of the diurnal acrophase induced no further increase
in plasma corticosterone levels in saline-pretreated ani-
mals (Fig. 5A). However, when endogenous steroid secre-
tion was suppressed by injection of 500 g methylpred-
nisolone, CRH was able to reinstate corticosterone
secretion, irrespective of whether it was administered dur-
ing the period of maximal rate of change (Fig. 5C) or the
period of maximal inhibition (Fig. 5D). Interestingly, this
FIG. 1. Corticosterone clearance rates and cross-reaction of
glucocorticoid agonists. Adrenalectomized animals each received iv
injections of corticosterone (CORT, 400 g), methylprednisolone
(PRED, 2000 g), and dexamethasone (DEX, 500 g). Blood samples
were assayed for corticosterone-like immunoreactivity. Inset shows the
period from 100–250 min on an enlarged scale. Values represent
mean  SEM (n  7).
Endocrinology, January 2012, 153(1):200–211 endo.endojournals.org 203
dose of CRH produced a persistent in-
crease in pituitary-adrenal activity. Sa-
line injection during the period of sup-
pression had no effect on
corticosterone levels (Fig. 5B), indicat-
ing that the stimulatory effect was not
due to nonspecific HPA activation.
Study 4: rapid glucocorticoid
suppression of stress-induced HPA
activity
To determine whether methylpred-
nisolone caused acute suppression of
centrally driven HPA activation, ste-
roid injections were performed before
a psychological stressor (30 min, 104
dB white noise). Preceding and imme-
diately after the injection of 500 g
methylprednisolone, corticosterone
levels did not differ between animals
receiving steroid or saline (Fig. 6).
In saline-treated animals, noise stress
evoked an increase in corticosterone
that was detectable after 10 min and
that reached a peak at 15 min from the
onset. Methylprednisolone-treated an-
imals showed no difference from saline
controls at 5 and 10 min after the onset
of noise, but thereafter, corticosterone
levels were significantly suppressed,
both during the stress and in the 10 min
after the end of the stimulus. Despite
the marked suppression of corticoste-
rone levels at this time, injection of 1g
CRH was able to evoke renewed secre-
tory activity.
The suppression of noise-induced
corticosterone levels by methylpred-
nisolone was confirmed in trunk blood
samples obtained from animals pre-
treated with different steroid doses
(Fig. 7A): 500 g, but not 5 or 50 g,
methylprednisolone reduced the levels
of corticosterone at the end of a 30-min
noise stress. This dose also attenuated
the levels of noise-induced c-fosmRNA
expression in the PVN (Fig. 7B).
FIG. 2. Acute iv injection of methylprednisolone (PRED) causes dose-dependent suppression
of basal corticosterone levels. Data show the mean  SEM of the absolute hormone levels (left
panels) and the data after normalization to the saline controls (right panels): A and F, Saline
controls, n  11; B and G, 5 g, n  8; C and H, 50 g, n  12; D and I, 500 g, n  12; E
and J, 2000 g, n  10 (see text for normalization procedure). All injections (indicated by the
broken line in each panel) were given at 1645 h when diurnal levels of circulating plasma
corticosterone are high. The hatched bar in each panel indicates the dark period commencing
at 1900 h. The asterisks in H–J show the first and last time points that are significantly
different from saline-injected animals (P  0.05). Note that the onset of feedback inhibition
does not occur until after 40 min after methylprednisolone injection. The dagger in J indicates
three successive samples that are significantly greater than the saline controls (P  0.05). The
horizontal lines in the right panels show the line of equality with saline values (i.e. normalized
values equal 1).
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Discussion
These data provide a detailed characterization of glu-
cocorticoid-induced rapid suppression of basal (non-
stimulated) HPA activity in the freely behaving rat.
They build on our initial observations of rapid HPA
suppression with methylprednisolone (8, 9, 23) and
show that this phenomenon involves
GR activation and is mediated, at
least in part, through a central site of
action, because pituitary-adrenal re-
sponses can be reactivated by exoge-
nous CRH when both spontaneous
(basal) and stress-induced HPA activ-
ity are suppressed. The data support
the evidence of corticosteroid-in-
duced rapid suppression of HPA ac-
tivity in humans (10, 29–34) and sug-
gest that observations of a finite
temporal delay between corticosteroid
administration and onset of the sup-
pressive response may arise from an
initial increase in corticosterone secre-
tion induced by high glucocorticoid
concentrations.
Dynamics of rapid HPA responses
to corticosteroids
Steroid negative feedback of the
HPA axis is thought to occur as a result
of plasma glucocorticoid concentra-
tions rising to levels that exceed the
range that is considered physiologically
homeostatic. The present data demon-
strate that an increase in GR activation
(either by methylprednisolone or dexa-
methasone) leads to dose-dependent
suppression of basal HPA axis activity.
The effect lasts up to several hours and
is reversible at lower doses but is subject
to a finite delay, with the earliest time
point when suppression is detected be-
ing 40 min after steroid injection.
Although rapid, rate-sensitive corti-
costeroid negative feedback was first
reported during the late 1960s and
1970s (40–42; reviewed in Ref. 7),
most studies involved indirect measures
or examination of the effect of steroids
on stimulated release. In respect of
basal (unstimulated) HPA activity, bo-
lus injection or infusion of a corticoste-
roid causes suppression of ACTH levels
in anesthetized and adrenalectomized rats (2.56 or 5.12
g corticosterone/100 gmin) (26) or dogs (bolus 292–317
g/kg cortisol) (28), and similar effects have been seen in
conscious and restrained intact dogs (3–22.5 g cortisol/
kgmin) (21). In all these cases, the suppression of ACTH
levels occurred after a time delay of 20–40 min, which did
FIG. 3. Effects of acute iv injection of dexamethasone (DEX) on basal corticosterone levels.
Data show the mean  SEM of the absolute hormone levels (left panels) and the data after
normalization to the saline controls (right panels): A and E, saline controls, n  11; B and F, 5
g, n  8; C and G, 50 g, n  6; D and H, 500 g, n  7. All injections (indicated by the
broken line in each panel) were given at 1645 h when diurnal levels of circulating plasma
corticosterone are high. The hatched bar in each panel indicates the dark period. The asterisks
in F–H show the first and last time points that are significantly different from saline-injected
animals (P  0.05). Note that the onset of feedback inhibition occurs only after 50 min after
DEX injection. The dagger in H indicates three successive samples that are significantly greater
than the saline controls (P  0.05). The horizontal lines in the right panels show the line of
equality with saline values (i.e. normalized values equal 1). Saline control data are the same as
in Fig. 2, A and E.
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not shorten with increasing steroid dose. More recently,
we showed that injectionsof eithermethylprednisolone (8,
9) or aldosterone (9) have rapid suppressive actions on
basal HPA activity in conscious rats. Using a single dose of
methylprednisolone (250 g), we showed that corticoste-
rone levels significantly declined below preinjection base-
line 33 min after steroid administration and remained low
for 4–5 h (9). Using a higher dose of methylprednisolone
(500 g), we showed that plasma corticosterone levels
significantly differed from saline-injected control animals
45–230 min after treatment (8). This is a similar duration
to that measured in the current study (significant effect
80–275 min after injection).
In contrast to the limited animal data, several reports
have described the effect of glucocorticoid administration
on basal HPA activity in man. Infusions of cortisol have
been shown to either have no effect (infusions of 6 and 12
mg/h cortisol for 2 h) (43) or an inhibitory effect (29–33)
on plasma ACTH/-lipotropin. For example, infusions of
2–6 mg/h of cortisol performed during the early part of the
day (i.e. near the diurnal peak similar to the present study)
caused a decline in ACTH levels after a delay of 30–45
min (29). Apparent recovery of ACTH secretion during
constant infusion led to the suggestion that this was a
rate-sensitive process, although persistent suppression at
higher doses indicated it was also level dependent. This has
been largely supported by subsequent studies. For exam-
ple, in a group of eight normal subjects, Goodwin et al.
(31) showed that a bolus infusion of 7 mg/kg cortisol
caused suppression of ACTH levels with onset 15–60 min
after the infusion. A similar result was found using a much
lower dose of steroid (33); a fall in ACTH levels was de-
tected 30–60 min after the start of a 2-h iv infusion of 15
mg cortisol. We recently showed that bolus injection of 10
mg methylprednisolone caused a significant decline in
ACTH after 60 min and cortisol after 70 min when tested
in the morning (i.e. during the diurnal acrophase) (10).
Measures of onset delay
It is important to note that to examine glucocorticoid-
mediated suppression of basal HPA activity, the present
studies were mostly performed during the late light phase
(1630–1800 h) when basal levels of corticosterone rise in
anticipation of the dark phase (in contrast to most other
studies performed during the nadir of HPA activity). Un-
der these conditions, measures from saline-treated ani-
mals showed corticosterone levels progressively changed
over the sampling period, possibly due to the combined
effects of the diurnal pattern and experimental proce-
dures. Thus, to accurately resolve the temporal dynamics
of glucocorticoid-induced suppression, each drug-in-
duced response was normalized to the control (saline-
treated) data and onset measured as a significant depar-
ture from 1. On this basis, the shortest delay between iv
injection of a glucocorticoid agonist and a significant
change in plasma corticosterone was 40 min (measured
after injection of 50 g methylprednisolone). This delay
will be the combined time required for the inhibitory pro-
cess to occur (effect) and the time for circulating cortico-
sterone to be cleared (detection). The clearance half-life of
corticosterone in the rat is very fast [measured here at5
min compared with previous estimates by ourselves of 8.6
min (37) and others of 9.3 min (44)]; therefore, we suggest
that much of this delay is due to the time for the inhibitory
mechanism to occur. However, an unexpected finding was
a dose-related rapid and transient increase in corticoste-
rone that was most evident at the higher agonist doses
(Figs. 2 and 3). This suggests that any lower-dose-associ-
FIG. 4. Effect of the GR antagonist RU38486 on the rapid inhibitory
effect of iv injection of 50 g methylprednisolone. Injection of
methylprednisolone (indicated by the broken line) was preceded by
injection of either 50 g (A, n  6) or 500 g (B, n  6) RU38486
(indicated by arrow). Data are the values after the normalization
procedure and are mean  SEM. The solid line in each panel shows the
mean response to 50 g methylprednisolone in the absence of
antagonist (data from Fig. 2H). The shaded areas in A indicate points
at which the antagonist-treated data differ significantly from
methylprednisolone alone (P  0.05, repeated-measures ANOVA). The
horizontal lines show the line of equality with saline values (i.e.
normalized values equal 1), and the hatched bar in each panel
indicates the dark period.
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ated HPA suppression occurring earlier than 40 min may
have been masked by an opposing stimulation. This in-
teraction between stimulatory and inhibitory effects of
steroid injection might account for the finite delay in HPA
suppression observed both in the present and earlier stud-
ies in animals (21, 26–28) and man (29, 33). Thus, al-
though rapid negative corticosteroid feedback occurring
within the 5 to 300 min time range has been incorporated
into models of the dynamic basal activity of the HPA (18),
it is clear from the present data that suppression of basal
HPA activity by the selective GR agonists methylpred-
nisolone and dexamethasone does not occur in this time
frame. Although it is possible that ligand affinity for the
p-glucoprotein (multidrug resistance protein 1) at the
blood-brain barrier may have contributed to the slower
dynamics of this response, the failure to shorten the onset
delay even at high doses and the fact that the transport
efficiency of p-glycoprotein for dexamethasone is the same
as cortisol (45) suggests that this is not a factor masking
rapid inhibition.
It is important to note that this apparent initial stimu-
lation was not a nonspecific response to the injections,
because it was both dose dependent and did not occur in
animals treated with saline or 5 g methylprednisolone.
Furthermore, the low cross-reactivity of methylpred-
nisolone and dexamethasone in our assay could not ac-
count for the large elevations in corticosterone-like im-
munoreactivity, particularly because the effect was most
marked with dexamethasone, which displays no cross-
reactivity. Interestingly, a study of normal human volun-
teers showed a trend for a similar immediate and transient
FIG. 6. Effect of acute glucocorticoid injection on noise stress-induced
corticosterone secretion during the diurnal nadir. Single injection of
methylprednisolone (PRED, 500 g, n  12, Œ) given 15 min before
the onset of a 30-min white noise stress (104 dB, shaded area) caused
a significant attenuation of the corticosterone response compared with
saline-injected controls (n  10, f). Asterisks indicate time points that
significantly differ between groups before injection of CRH (P  0.05,
repeated-measures ANOVA). Injection of CRH (1 g, iv) at 100 min
confirmed pituitary-adrenal responsiveness. Data are mean  SEM.
FIG. 5. Effect of CRH on corticosterone secretion during methylprednisolone-induced negative feedback. A, Injection of CRH (1 g, iv) 60 min
after an injection of saline has little effect on basal HPA activity during the late light phase of the diurnal cycle (n  4). B, Injection of
methylprednisolone (PRED, 500 g, iv) caused rapid and sustained suppression of corticosterone levels that was unaffected by subsequent
injection of saline (n  3). CRH injection was able to cause a rapid increase in corticosterone levels when given either 60 min after
methylprednisolone during the maximal rate of suppression (C, n  12) or at 240 min when corticosterone levels had reached a nadir (D, n  4).
Values are mean  SEM. Hatched bar shows the dark period. Note that for injections performed during the dark period (B and D), animals were
exposed to a brief period of light.
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increase in ACTH levels after injection of a dose of cortisol
similar to our highest dose of methylprednisolone (7
mg/kg equivalent to 2 mg/rat) (31), an effect that is not
seen with a much lower dose (25 mg bolus equivalent to
100 g/rat) (34). One possible mechanism for this stim-
ulation may be an interaction with CRH. In cultured
equine pituitary cells, cortisol has been shown to inhibit
ACTH release in conditions without CRH and have no
effect with low levels of CRH (2 pM) but to potentiate
ACTH release at higher (20 pM) CRH levels (46). Because
endogenous CRH levels would be elevated at the time of
injection as a drive to the diurnal rhythm of HPA activity,
such an interaction might also occur in vivo.
GR involvement
Data obtained using various receptor ligands indicate
that the rapid suppression of HPA activity is mediated
through a GR-like mechanism. We have shown (9) that
although the mineralocorticoid receptor (MR)-selective
agonist aldosterone (250 g) has a transient suppressive
effect on corticosterone levels, injection of methylpred-
nisolone (which has one tenth of the MR activity of aldo-
sterone but20-fold greater GR activity) (47) had a much
greater and long-lasting effect, indicating that GR activa-
tion may play the predominant role in fast feedback mech-
anisms. This is borne out by the current data showing the
effect of dexamethasone that, although having similar MR
activity to methylprednisolone, has a 6- to 12-fold greater
GR potency (47) and was approximately 10-fold more
effective at suppressing HPA activity. Furthermore, the
GR antagonist RU38486 attenuated the effects of meth-
ylprednisolone and at high dose displayed evidence of a
stimulation, suggesting that GR activation by endogenous
corticosteroids may have a role in regulating HPA activity
during the diurnal acrophase. That rapid suppression is a
GR-mediated phenomenon is consistent with our studies
in man (10), which showed that the MR antagonist spi-
ronolactone did not affect the suppression of ACTH by
methylprednisolone (10 mg/subject), whereas RU38486
attenuated this effect. There are few other data on the fast
actions of GR-selective ligands on basal HPA activity with
which to compare. However, iv injection of 15 g/kg
dexamethasone in conscious cats has been shown to cause
marked suppression of cortisol 2 h later (the first time
point measured) (48), and sc injection of 25 or 50 g/kg
dexamethasone to rats significantly reduces corticoste-
rone 90 min later (11). Interestingly, despite being more
potent than methylprednisolone, dexamethasone showed
a similar finite minimal delay to inhibition (40 min) and
a similar rapid and transient stimulation, again sup-
porting the existence of a rapid GR-mediated activa-
tion. It is, however, important to be aware of the caveat
that both methylprednisolone and dexamethasone have
markedly different effects on GR-DNA binding dynam-
ics to native hormones cortisol and corticosterone (49),
and this is very likely to contribute to the biological effects
of these ligands. Furthermore, the possible importance of
cooperativity between MR and GR, and even the poten-
tial importance of MR-GR heterodimerization remains
unexplored.
Site of fast inhibitory actions
Rat studies have shown attenuation of the HPA re-
sponse when corticosteroids are peripherally administered
shortly before exposure to a variety stressors, e.g. restraint
(14, 50), air puff startle (24), insulin-induced hypoglyce-
FIG. 7. Glucocorticoid-induced suppression of HPA and c-fos mRNA
response to noise stress. A, Injection of methylprednisolone (5–500 g)
15 min before a 30-min noise stress significantly attenuated
corticosterone levels measured from trunk blood samples obtained
immediately after the end of the noise. *, P  0.001, 500-g dose vs.
either saline or 5-g dose (one-way ANOVA followed by post hoc
Tukey’s test). Corticosterone levels in animals receiving no noise were
not determined (n.d.). B, Expression of c-fos mRNA in the
hypothalamic PVN of animals receiving either saline or an acute dose
of methylprednisolone (5–500 mg) 15 min before a 30-min noise
stress. A second control group (no noise) is also included. *, P  0.05,
saline vs. 5 mg (one-way ANOVA followed by post hoc Tukey’s test).
C, Example autoradiograms of the PVN region in three treatment
groups.
208 Andrews et al. Glucocorticoids Rapidly Suppress HPA Axis Endocrinology, January 2012, 153(1):200–211
mia (21), and photic and acoustic stressors (51), although
not to others, e.g. hemorrhage (24). The present protocol
(injection of 500 g methylprednisolone 15 min before a
30-min noise stress) is similar to that which we used pre-
viously to examine attenuation of stress-induced HPA ac-
tivity (2000g administered 40 min before a 10-min noise
stress) (23) and confirms that inhibitory mechanisms are
activated within a rapid time frame. Likewise, Ginsberg et
al. (14) showed that treatment with corticosterone (5 mg/
kg) or a GR agonist RU28362 (150 g/kg) 1 h before
restraint attenuates the neuroendocrine response. The
present data show that although acute glucocorticoid ad-
ministration suppressed corticosterone secretion, injec-
tion of exogenous CRH was able to reactivate cortisol
release, even at the peak of corticosteroid-induced sup-
pression. The fact that exogenous CRH was ineffective
before steroid administration (presumably due to the al-
ready high endogenous CRH drive during the diurnal ac-
rophase) but was effective once the system was inhibited
is consistent with a central site of action. Furthermore,
methylprednisolone blocked stress-induced corticoste-
rone release and PVN activation (measured by levels of
c-fos mRNA) but not the response to CRH. These data
clearly indicate a suprapituitary site of action and suggest
either that the limited brain penetration of prednisolone
demonstrated in the mouse (52) does not operate in the rat
or that the amount of glucocorticoid that enters is suffi-
cient to have a functional effect.
Although glucocorticoid feedback may operate at sev-
eral sites, including hippocampus, a PVN site of action is
supported by recent evidence of rapid suppression of re-
straint-induced HPA activity after direct intra-PVN injec-
tion of dexamethasone (53), although in this study, stress-
induced Fos expression was unaffected. Other studies
have also shown that restraint-induced c-fos mRNA or
Fos protein induction in the PVN are unaffected by acute
GR agonist treatment but noted that CRH heteronuclear
RNA induction was blocked (14, 50). Compared with the
present data, these differences in the effect of acute corti-
costeroids on Fos may be due to the use of 30 min restraint
compared with the relatively mild stress of 30 min noise
used here. Alternatively, it may be that under certain con-
ditions, the PVN may still be activated, and the target for
steroid feedback is the pituitary. In this regard, Hinz and
Hirschelmann (12) showed that CRH-induced ACTH se-
cretion could be attenuated by iv treatment of rats with a
range of glucocorticoid agonists (cortisol, corticosterone,
RU28362, and dexamethasone) administered at the same
time as the CRH injection. Interestingly, this suppressive
action was unaffected by previous treatment with 250-
fold excess of RU38486 given 45 min before the steroid
(12), suggesting that this pituitary effect differs from the
GR-like effect we report. Although it is possible that en-
dogenous corticosterone has additional effects to those of
the selective GR agonists used here, studies of rapid effects
of glucocorticoids have indicated that dexamethasone has
similar effects to cortisol (12) and is able to rapidly block
stress-induced HPA activity when injected centrally (53).
The site of rapid glucocorticoid feedback may also be spe-
cies specific. In man, we recently showed that a dose of 10
mg methylprednisolone (equivalent to about 100 g/kg)
not only suppressed basal ACTH and cortisol but also
completely blocked the response to 1 g/kg CRH (10),
indicating that one site of action for rapid negative feed-
back was the pituitary. In contrast, the present data show
that a considerably higher dose of methylprednisolone
(500 g, equivalent to about 1500 g/kg) despite com-
pletely suppressing corticosterone secretion failed to block
the response to exogenous CRH. It will be interesting to
explore the mechanisms underlying this difference in pi-
tuitary sensitivity.
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